Cargando…
Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise he...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271636/ https://www.ncbi.nlm.nih.gov/pubmed/32499597 http://dx.doi.org/10.1038/s41372-020-0689-y |
_version_ | 1783542123286495232 |
---|---|
author | Krilov, Leonard R. Anderson, Evan J. |
author_facet | Krilov, Leonard R. Anderson, Evan J. |
author_sort | Krilov, Leonard R. |
collection | PubMed |
description | Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise healthy 29–34 wGA infants, stating that their risk of RSV hospitalization (RSVH) was similar to term infants. Recent studies have demonstrated a significant decline in IP use after 2014 that was accompanied by an increased risk of RSVH in 29–34 wGA infants vs term infants. Severity and healthcare utilization of RSVH were high among 29–34 wGA infants. In 2018, the National Perinatal Association developed guidelines advocating IP use in all ≤32 wGA infants and 32–35 wGA infants with additional risk factors. Risk factor predictive models can identify infants who are at risk for RSVH and promote cost-effective use of palivizumab until new methods of RSV prevention become available. |
format | Online Article Text |
id | pubmed-7271636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-72716362020-06-04 Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics Krilov, Leonard R. Anderson, Evan J. J Perinatol Review Article Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise healthy 29–34 wGA infants, stating that their risk of RSV hospitalization (RSVH) was similar to term infants. Recent studies have demonstrated a significant decline in IP use after 2014 that was accompanied by an increased risk of RSVH in 29–34 wGA infants vs term infants. Severity and healthcare utilization of RSVH were high among 29–34 wGA infants. In 2018, the National Perinatal Association developed guidelines advocating IP use in all ≤32 wGA infants and 32–35 wGA infants with additional risk factors. Risk factor predictive models can identify infants who are at risk for RSVH and promote cost-effective use of palivizumab until new methods of RSV prevention become available. Nature Publishing Group US 2020-06-04 2020 /pmc/articles/PMC7271636/ /pubmed/32499597 http://dx.doi.org/10.1038/s41372-020-0689-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Krilov, Leonard R. Anderson, Evan J. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title | Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title_full | Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title_fullStr | Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title_full_unstemmed | Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title_short | Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics |
title_sort | respiratory syncytial virus hospitalizations in us preterm infants after the 2014 change in immunoprophylaxis guidance by the american academy of pediatrics |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271636/ https://www.ncbi.nlm.nih.gov/pubmed/32499597 http://dx.doi.org/10.1038/s41372-020-0689-y |
work_keys_str_mv | AT krilovleonardr respiratorysyncytialvirushospitalizationsinuspreterminfantsafterthe2014changeinimmunoprophylaxisguidancebytheamericanacademyofpediatrics AT andersonevanj respiratorysyncytialvirushospitalizationsinuspreterminfantsafterthe2014changeinimmunoprophylaxisguidancebytheamericanacademyofpediatrics |